Astrazeneca PLC 6-K, filed Jan 13, 2020
Astrazeneca PLC (AZN)
6-K
2020-01-13
For: 2020-01-13
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on January 13, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of January 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Lynparza
regulatory submission granted Priority Review in the US for
1st-line maintenance treatment with bevacizumab in advanced ovarian
cancer
13 January 2020 07:00 GMT
Lynparza regulatory submission granted Priority
Review in the US for 1st-line maintenance treatment with
bevacizumab in advanced ovarian cancer
Submission based on Phase III PAOLA-1 trial for patients with
advanced
ovarian cancer regardless of biomarker status or surgical
outcome
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck
& Co., Inc. inside the US and Canada) today announced that
a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab
has been accepted and granted Priority Review in the US
for the maintenance treatment of patients with advanced ovarian
cancer who are in complete or partial response to 1st-line
platinum-based chemotherapy with bevacizumab.
A Prescription Drug User Fee Act (PDUFA) date is set for the second
quarter of 2020.
The Priority Review by the US Food and Drug Administration
(FDA) was based on results from the pivotal Phase III
PAOLA-1 trial, which were published in The
New England Journal of Medicine. The trial compared Lynparza when added to standard-of-care (SoC)
bevacizumab vs. bevacizumab alone in patients with advanced ovarian
cancer in the 1st-line maintenance setting, regardless of their
biomarker status or outcome from previous
surgery.
The investigator-assessed results showed Lynparza added to bevacizumab reduced the risk of
disease progression or death by 41% based on a hazard ratio of 0.59
(p<0.0001) and improved progression-free survival (PFS) to
a median of 22.1 months vs. 16.6 months for patients treated with
bevacizumab alone.
At two years after trial initiation, 46% of patients treated
with Lynparza added to bevacizumab showed no disease
progression vs. 28% of patients treated with bevacizumab alone. The
safety and tolerability profiles of Lynparza and bevacizumab were consistent with
previous trials for each medicine and showed no detriment to
quality of life.
Lynparza is the only PARP
inhibitor with two positive randomised Phase III trials in the
1st-line maintenance setting for advanced ovarian cancer. It is the
only PARP inhibitor approved in the
US as a 1st-line
maintenance treatment for patients with BRCA-mutated advanced
ovarian cancer, based on the SOLO-1 trial. If approved, this would
be the fourth indication for ovarian cancer patients in the US
for Lynparza.
Ovarian cancer
Ovarian cancer is the eighth most common cause of death from cancer
in women worldwide. In 2018, there were nearly 300,000 new cases
diagnosed and around 185,000 deaths.1 Most women are diagnosed with advanced (Stage III
or IV) ovarian cancer and have a five-year survival rate of
approximately 30%.2 For newly diagnosed advanced ovarian cancer, the
primary aim of treatment is to delay progression of the disease for
as long as possible and maintain the patient's
quality of life with the intent of achieving complete
remission or cure.3,4,5,6
PAOLA-1
PAOLA-1
is a double-blind Phase III trial testing the efficacy and safety
of Lynparza added
to standard-of-care bevacizumab vs. bevacizumab alone, as a
1st-line maintenance treatment for newly diagnosed advanced FIGO
Stage III-IV high-grade serous or endometroid ovarian, fallopian
tube, or peritoneal cancer patients who had a complete or partial
response to 1st-line treatment with platinum-based chemotherapy and
bevacizumab.
Results
showed Lynparza added to bevacizumab
demonstrated a statistically significant and clinically meaningful
improvement in PFS, reducing the risk of disease progression or
death by 41% and improving PFS to a median of 22.1 months versus
16.6 months for those treated with bevacizumab alone (HR 0.59 [95%
CI, 0.49-0.72], p<0.0001). The sensitivity analysis of blinded
independent central review (BICR) of PFS was consistent, showing a
similar improvement with a median of 26.1 months
for Lynparza added to bevacizumab vs.
18.3 months for bevacizumab alone (HR 0.63 [95% CI, 0.51-0.77],
p<0.0001).
Overall
Grade 3 or above adverse events (AEs) were 57%
for Lynparza added
to bevacizumab and 51% for bevacizumab alone. The most common AEs
≥20% were nausea (53%), fatigue (53%), hypertension (46%),
anaemia (41%), lymphopenia (24%), vomiting (22%) and arthralgia
(22%). Grade 3 or above AEs were hypertension (19%), anaemia (17%),
lymphopenia (7%), neutropenia (6%), fatigue (5%), nausea (2%),
diarrhoea (2%), leukopenia (2%) vomiting (1%) and abdominal pain
(1%). AEs led to dose interruption in 54% of patients
on Lynparza added
to bevacizumab while 20% of patients discontinued
treatment.
PAOLA-1
is an ENGOT (European Network of Gynaecological Oncological Trial
groups) trial, sponsored by ARCAGY Research (Association de
Recherche sur les CAncers dont GYnécologiques) on behalf of
GINECO (Groupe d'Investigateurs National des Etudes des Cancers
Ovariens et du sein). ARCAGY-GINECO is an academic group
specialising in clinical and translational research in patients'
cancers and a member of the GCIG (Gynecologic Cancer
InterGroup).
Lynparza
Lynparza (olaparib) is a first-in-class PARP
inhibitor and the first targeted treatment to block DNA damage
response (DDR) in cells/tumours harbouring a deficiency in
homologous recombination repair, such as mutations in BRCA1 and/or
BRCA2. Inhibition of PARP with Lynparza leads to the trapping of
PARP bound to DNA single-strand breaks, stalling of replication
forks, their collapse and the generation of DNA double-strand
breaks and cancer cell death. Lynparza is being tested in a
range of PARP-dependent tumour types with defects and dependencies
in the DDR pathway.
Lynparza is currently approved in 65 countries,
including those in the EU, for the maintenance treatment of
platinum-sensitive relapsed ovarian cancer, regardless of BRCA
status. It is approved in the US, the EU, Japan, China and several
other countries as 1st-line maintenance treatment of BRCA-mutated
advanced ovarian cancer following response to platinum-based
chemotherapy. It is also approved in 44 countries, including the US
and Japan, for germline BRCA-mutated, HER2-negative, metastatic
breast cancer, previously treated with chemotherapy; in the EU,
this includes locally advanced breast cancer. It is approved in the
US as a 1st-line maintenance treatment for germline BRCA-mutated
metastatic pancreatic cancer. Regulatory reviews are underway in
other jurisdictions for ovarian, breast and pancreatic
cancers.
Lynparza, which is being jointly developed and
commercialised by AstraZeneca and MSD, is approved for the
treatment of advanced ovarian cancer, metastatic breast cancer and
metastatic pancreatic cancer and has been used to treat over 30,000
patients worldwide. Lynparza has the broadest and most
advanced clinical-trial development programme of any PARP
inhibitor, and AstraZeneca and MSD are working together to
understand how it may affect multiple PARP-dependent tumours as a
monotherapy and in combination across multiple cancer
types. Lynparza is the foundation of
AstraZeneca's industry-leading portfolio of potential new medicines
targeting DDR mechanisms in cancer cells.
The AstraZeneca and MSD strategic oncology
collaboration
In July
2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US,
known as MSD outside the US and Canada, announced a global
strategic oncology collaboration to co-develop and
co-commercialise Lynparza, the world's first PARP
inhibitor, and potential new medicine selumetinib, a MEK inhibitor,
for multiple cancer types. Working together, the companies will
develop Lynparza and selumetinib in
combination with other potential new medicines and as
monotherapies. Independently, the companies will
develop Lynparza and selumetinib in
combination with their respective PD-L1 and PD-1
medicines.
AstraZeneca in oncology
AstraZeneca has a deep-rooted heritage in oncology and offers a
quickly growing portfolio of new medicines that has the potential
to transform patients' lives and the Company's future. With at
least six new medicines to be launched between 2014 and 2020, and a
broad pipeline of small molecules and biologics in development, the
Company is committed to advance oncology as a key growth driver for
AstraZeneca focused on lung, ovarian, breast and blood cancers. In
addition to AstraZeneca's main capabilities, the Company is
actively pursuing innovative partnerships and investment that
accelerate the delivery of our strategy, as illustrated by the
investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms -
Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates - and by championing the development
of personalised combinations, AstraZeneca has the vision to
redefine cancer treatment and, one day, eliminate cancer as a cause
of death.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
|
Media
Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203
749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203
749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301
518 4122
|
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203
749 5906
|
|
Jennifer
Hursit
|
Other
|
+44
203 749 5762
|
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
BioPharmaceuticals
(Cardiovascular, Metabolism)
|
+44 203
749 5711
|
|
Nick
Stone
|
BioPharmaceuticals
(Renal)
Environmental,
Social and Governance
|
+44 203
749 5716
|
|
Josie
Afolabi
|
BioPharmaceuticals
(Respiratory)
Other
medicines
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance
Fixed
income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate
access
Retail
investors
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 72 77
|
References
1. The World Health
Organization. IARC. Globocan 2018. Available
at: www.gco.iarc.fr/ [Accessed
December 2019].
2. National Cancer Institute. (2019).
Cancer Stat Facts: Ovarian Cancer Available
at: https://seer.cancer.gov/statfacts/html/ovary.html [Accessed
December 2019].
3.
Moore K et al. Maintenance Olaparib in Patients with Newly
Diagnosed Advanced Ovarian Cancer. Presented at ESMO
October 2018.
4. Raja, F. A., Chopra, N. &
Ledermann, J. A. 2012. Optimal first-line treatment in ovarian
cancer. Annals of Oncology. Official
Journal of the European Society for Medical
Oncology. 23 Suppl 10,
x118-127.
5. NHS Choices. Ovarian Cancer.
Available at: https://www.nhs.uk/conditions/ovarian-cancer/treatment/ [Accessed
December 2019].
6. Ledermann.et al. 2013. Newly
diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical
Practice for diagnosis, treatment and
follow-up. Annals of
Oncology, 24(suppl 6),
pp.vi24-vi32.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
13 January 2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|